JB Pharma's PAT Rises By 4%, Revenues Up By 22% IN Q4FY23

JB Pharma an Indian pharmaceutical company announced its financial results for the fourth quarter and year ended 31st March, 2022 on Wednesday. The company recorded revenue of  Rs 762 crores in the fourth quarter ended 31st March 2023 against Rs 625 crores in Q4FY22 registering growth of 22 per cent YoY. 

In Q4FY23 operating EBITDA(Earnings Before Interest Depreciation and Taxes) increased by 21 per cent YoY to Rs 181 crores as compared to Rs 149 crores in Q4FY22. Profit after Tax stood at Rs 88 crores as compared to Rs 85 crores registering growth of 4 per cent YoY.

For the financial year 2022-23, the company recorded revenue of Rs 3,149 crores as compared to Rs 2,424 crores in FY22, registering a growth of 30 per cent. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) registered growth of 26 per cent to Rs 765 crores as compared to Rs 605 crores in FY22. Profit after Tax was Rs 410 crores as compared to Rs 386 crores recording a growth of 6 per cent.

Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated "Each of our top 5 brands have ascended through the ranks. Further, Azmarda entered IQVIA’s Top 300 brands list and other acquired businesses in probiotics and pediatric segment have witnessed rank and market share gain."

Chopra further said, "Our performance in International business has seen commendable gains amidst a challenging business environment. International formulations clocked mid-teens growth for the quarter. We continue to witness increased interest from existing and new clients in the CMO business especially in the lozenges segment. We expect to build on this growth in the long term by expanding our pipeline for international business."